# Sixty Degree Capital

> Sixty Degree Capital is a VC fund backing Biotechnology and Health Care. See 53 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Toronto, Canada
- Total investments: 53
- Last investment: Jun 2026
- Lead investor: 0%
- Last fund: Dec 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sixtydegreecapital
- Website: https://www.sixtydegreecapital.com/

Sixty Degree Capital is a North American VC that invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO). The firm has a global investment mandate, but currently focuses on the US market.

## Contacts

5 contacts available for Sixty Degree Capital. Shizune tracks 1 team members at Sixty Degree Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/quantum-vista-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 19 | 36% |
| Health Care | 14 | 26% |
| Therapeutics | 9 | 17% |
| Software | 7 | 13% |
| Pharmaceutical | 7 | 13% |

52 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 11 | 21% |
| Series D | 7 | 13% |
| Series C | 6 | 11% |
| Series E | 6 | 11% |
| Series A | 5 | 9% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 29 | 55% |
| Canada | 2 | 4% |
| Germany | 2 | 4% |
| Switzerland | 2 | 4% |
| China | 1 | 2% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Yatong Li | Managing Director | 0 | https://shizune.co/investors/profile/yatong-li |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Straiker | Straiker builds AI-native security solutions tp protect customers from a spectrum of security & safety risks. | $64M | Series A | Jun 29, 2026 |  |
| Bionyra | Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M | Series A | Jun 22, 2026 |  |
| Eclypsium | Eclypsium protects organizations from the foundation of their computing infrastructure upward, controlling the risk and stopping threats inside firmware of laptops, servers, and networking infrastructure. | $25M | Series C | Mar 19, 2026 |  |
| Crossbow Therapeutics | Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M | Series B | Mar 18, 2026 |  |
| HawkEye 360 | HawkEye 360 is a data analytics company that develops space-based radio frequency mapping. The company operates a commercial satellite constellation to identify, process, and geolocate a broad set of RF signals. Its products include maritime domain awareness and spectrum mapping and monitoring; our customers include a wide range of commercial,government, and international entities.It was founded in 2015 and is headquartered in Herndon, Virginia. | $23M | Series E | Mar 04, 2026 |  |
| Kinaset Therapeutics | Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M | Series B | Jan 10, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| AAVantgarde Bio | AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M | Series B | Nov 03, 2025 |  |
| Droidrun | Droidrun is a cutting-edge software development company that specializes in creating innovative solutions enabling AI agents to seamlessly access and control smartphone applications. By leveraging advanced artificial intelligence and machine learning algorithms, their software facilitates smooth interactions between AI systems and mobile devices,empowering agents to autonomously navigate, operate, and optimize a wide range of apps on both Android and iOS platforms. | $2.5M | Pre-Seed | Jul 23, 2025 |  |
| Empirical Security | Empirical builds mathematical models for security data. | $11.9M | Seed | Jul 17, 2025 |  |

10 of 53 investments shown.

## Co-investors
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 9 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 7 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 7 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 7 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 6 deals together
- [Soleus Capital](https://shizune.co/investors/profile/soleus-capital) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund

## Featured in investor lists
- [Infrastructure Investors in Germany](https://shizune.co/investors/infrastructure-investors-germany)
- [Infrastructure Investors in Europe](https://shizune.co/investors/infrastructure-investors-europe)

## FAQ

### What does Sixty Degree Capital invest in?

Sixty Degree Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series D stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sixty Degree Capital?

Public channels for Sixty Degree Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sixty Degree Capital?

The team at Sixty Degree Capital includes Yatong Li (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co